ArticleBMC musculoskeletal disorders2025
Semitendinosus vs quadriceps tendon autograft in anterior cruciate ligament reconstruction (SEQUAR): protocol for a prospective randomized controlled trial.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04295148 (SEQUAR - SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SEQUAR - SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnterior cruciate ligament (ACL) rupture is a devastating injury for most individuals, especially in athletes with the desire to go back to pivoting sports. In ACL reconstruction (ACL-R), multiple autograft options are available, each with distinct advantages and limitations. The quadriceps tendon (QT) autograft has gained increasing attention due to its favorable biomechanical properties and lower donor site morbidity, yet studies comparing only athletic populations remains limited. This study protocol describes a randomized controlled trial (RCT) aiming to compare QT autograft with bone-block (QT-B) with semitendinosus tendon (ST) autograft in athletes undergoing primary ACL-R.
methodsThis is a single center RCT. Two Hundred ACL-R patients aged 16-40 years with a Tegner Activity Scale (TAS) of ≥ 7 prior to the ACL injury will be randomized to receive either a ST graft or a QT-B graft at the time of ACL-R. All participants will receive standard postoperative care and rehabilitation, followed by comprehensive follow-up. The primary outcome was the side-to-side (STS) difference in anterior tibial translation (ATT) at 6 months. Secondary outcomes include patient-reported outcome measures (PROMs), isokinetic strength testing, imaging-based graft evaluation, surgical and clinical events, and 10-year radiographic evidence of joint degeneration. Detailed definitions and timepoints are provided in the full manuscript (Table 1). DISCUSSION: This protocol is the first RCT comparing the ST autograft to the QT-B autograft exclusively in athletes with TAS ≥ 7 undergoing ACL-R. In addition, this trial has the ambition of including 200 patients, thereby making it the largest trial to compare these two grafts to date. The successful completion of the trial has the potential to change current practice and contribute to the existing knowledge regarding graft choice in athletes undergoing ACL-R.
trial registrationThe trial is registered at ClinicalTrials.gov: NCT04295148. Registered date: 4 Mar 2020 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.